Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
Company profile
Ticker
PRPO
Exchange
Website
CEO
Paul Kinnon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Bio-Rad Laboratories • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Perkinelmer • Seer • Cue Health ...
Former names
TRANSGENOMIC INC
SEC CIK
Corporate docs
Subsidiaries
Precipio Diagnostics, LLC • Precipio SPV, Inc. ...
IRS number
911789357
PRPO stock data
Latest filings (excl ownership)
8-K
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
29 Mar 23
8-K
Other Events
21 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Precipio Announces Third Quarter Shareholder Update Call
3 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Oct 22
8-K
Other Events
19 Sep 22
8-K
Other Events
19 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Precipio Announces Second Quarter Shareholder Update Call
8 Aug 22
8-K
Agreement Enhances Precipio’s Product Reach to US Laboratories
20 Jul 22
Transcripts
PRPO
Earnings call transcript
2022 Q2
16 Aug 22
PRPO
Earnings call transcript
2021 Q4
4 Apr 22
PRPO
Earnings call transcript
2021 Q3
16 Nov 21
PRPO
Earnings call transcript
2021 Q2
27 Aug 21
PRPO
Earnings call transcript
2021 Q1
21 May 21
PRPO
Earnings call transcript
2020 Q4
1 Apr 21
PRPO
Earnings call transcript
2020 Q3
19 Nov 20
PRPO
Earnings call transcript
2020 Q2
17 Aug 20
PRPO
Earnings call transcript
2020 Q1
19 May 20
PRPO
Earnings call transcript
2019 Q3
13 Nov 19
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 5.14 mm | 5.14 mm | 5.14 mm | 5.14 mm | 5.14 mm | 5.14 mm |
| Cash burn (monthly) | 776.33 k | 673.25 k | 1.08 mm | 1.11 mm | 747.00 k | 638.50 k |
| Cash used (since last report) | 4.66 mm | 4.04 mm | 6.47 mm | 6.70 mm | 4.49 mm | 3.84 mm |
| Cash remaining | 480.56 k | 1.10 mm | -1.32 mm | -1.55 mm | 656.77 k | 1.31 mm |
| Runway (months of cash) | 0.6 | 1.6 | -1.2 | -1.4 | 0.9 | 2.0 |
Institutional ownership, Q3 2022
1.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 18 |
| Opened positions | 0 |
| Closed positions | 2 |
| Increased positions | 3 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 1.67 mm |
| Total shares | 2.08 mm |
| Total puts | 0.00 |
| Total calls | 16.70 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 1.05 mm | $845.00 k |
| BLK Blackrock | 579.47 k | $466.00 k |
| Geode Capital Management | 257.13 k | $206.00 k |
| Great Valley Advisor | 33.10 k | $27.00 k |
| NTRS Northern Trust | 32.05 k | $26.00 k |
| Stratos Wealth Partners | 30.00 k | $24.00 k |
| Renaissance Technologies | 23.00 k | $18.00 k |
| Dimensional Fund Advisors | 17.18 k | $14.00 k |
| Group One Trading | 16.42 k | $13.00 k |
| Tower Research Capital | 11.75 k | $9.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Jan 23 | Sandberg Richard A | Common Stock | Buy | Acquire P | No | No | 0.7765 | 20,000 | 15.53 k | 40,846 |
| 6 Jan 23 | Andrews Ronald Asbury | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
| 6 Jan 23 | Fisher Douglas | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
| 6 Jan 23 | Cossman Jeffrey | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
| 6 Jan 23 | Cohen David Seth | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 30,000 | 18.60 k | 30,000 |
News
Precipio Ships First IV-Cell Order To Major U.S. Healthcare System
21 Mar 23
12 Health Care Stocks Moving In Monday's After-Market Session
13 Mar 23
Precipio Continues To Sign Up And Onboard Hemescreen Customers, With An Additional Recently Signed Agreement Expected To Generate Annualized Revenues Exceeding $125,000
7 Mar 23
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
24 Jan 23
12 Health Care Stocks Moving In Monday's Pre-Market Session
23 Jan 23
Press releases
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
28 Mar 23
Precipio Ships First IV-Cell® Order to Major US Healthcare System
21 Mar 23
Precipio continues to sign up and onboard HemeScreen™ customers
7 Mar 23
ThermoFisher Salesforce Votes Precipio's HemeScreen® as "Best New Product"
14 Feb 23